Finding – Talk Bio

Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting Durable Complete Response and 66.7% ORR in Advanced GC/GEJ

3 days ago talkbio0Tagged ASCO GI 2026, CAR-T, Claudin-18 Isoform A2, IMC002, Immunofoco, In complete remission, Malignant neoplasm of stomach, ORR

Immunofoco; IMC002; ASCO GI 2026; CAR-T; CLDN18.2; gastric cancer; complete response; ORR

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

7 days ago talkbio0Tagged Autoimmune, cardiometabolic, Eli, Eli Lilly, Immunotherapy for cancer, InduPro * *, Inflammatory disorder, M&A, Neoplasms, Neuroinflammation, NLRP3 inhibitors, Obesity, Ventyx Biosciences, VTX3232, VTX958

Eli Lilly; Lilly; Ventyx Biosciences; InduPro; inflammatory diseases; oncology; NLRP3 inhibitors; tamuzimod; VTX2735; VTX3232; VTX958; autoimmune; obesity; cardiometabolic; neuroinflammation; M&A; biotech deal; cancer immunotherapy

Enliven’s Phase 1b ELVN‑001 leukemia pill shows competitive efficacy vs. Novartis and Terns CML TKIs

7 days ago talkbio0Tagged asciminib, BCR-ABL1, Contraceptives, Oral, Deep molecular response, ELVN-001, ENABLE trial, Enliven Therapeutics, Inhibitor, Measles-Mumps-Rubella Vaccine, Molecular Response, Myeloid Leukemia, Chronic, Novartis, Phase 1b, Protein-tyrosine kinase inhibitor, T315I, TERN-701, Terns, TKI, WDR20 gene

Enliven Therapeutics; ELVN-001; Phase 1b; chronic myeloid leukemia; CML; BCR-ABL1 inhibitor; major molecular response; MMR; deep molecular response; DMR; asciminib; Novartis; Terns Pharmaceuticals; TERN-701; T315I; ENABLE trial; CML pill; tyrosine kinase inhibitor; TKI; best-in-class

Lilly to acquire Ventyx Biosciences for ~$1.2B to add oral NLRP3 and other inflammatory drugs

1 week ago talkbio0Tagged Acquisition, Autoimmune Diseases, cardiometabolic, Eli, Eli Lilly, Inflammatory disorder, Neuroinflammation, NLRP3 inhibitors, oral therapies, Ventyx Biosciences

Eli Lilly; Ventyx Biosciences; $1.2 billion; acquisition; NLRP3 inhibitors; VTX3232; VTX2735; inflammatory diseases; oral therapies; cardiometabolic; neuroinflammation; autoimmune diseases

FDA Memo Claims COVID Vaccine Linked to 10 Child Deaths, Faces Expert Skepticism and Criticism

1 week ago talkbio0Tagged COVID, Death of child, MEMO1 gene, United States Food and Drug Administration, Vaccine Safety, Vaccines, VAERS, Vinay Prasad

FDA memo; COVID vaccine; child deaths; Vinay Prasad; VAERS; vaccine safety

Arrowhead’s RNAi Obesity Programs ARO-INHBE and ARO-ALK7 Advance with Encouraging Phase 1/2a Data

1 week ago talkbio0Tagged ARO-ALK7, ARO-INHBE, Arrowhead Pharmaceuticals, Obesity, Phase 1/2a, RNA Interference, tirzepatide, Weight Loss, Zepbound

Arrowhead Pharmaceuticals; ARO-INHBE; ARO-ALK7; RNAi; obesity; Phase 1/2a; tirzepatide; Zepbound; weight loss

Novo Nordisk Launches Wegovy Pill in the US with Broad Availability

1 week ago talkbio0Tagged Glucagon-Like Peptide 1, January 2026, Novo Nordisk, Oral cavity, U.S., Wegovy pill, Weight Loss

Novo Nordisk; Wegovy pill; US launch; January 2026; oral GLP-1; weight loss

GSK wins FDA approval for ultra-long-acting asthma drug Exdensur (depemokimab)

4 weeks ago talkbio0Tagged Approved, Asthma, biology (field), Depemokimab, dosing, eosinophilic, Exdensur, IL-5 Inhibitor, Phenotype, Severe (severity modifier), SmithKline Beecham, twice-yearly, type 2 inflammation, ultra-long acting, United States Food and Drug Administration

GSK; Exdensur; depemokimab; FDA approval; severe asthma; ultra-long-acting biologic; twice-yearly dosing; type 2 inflammation; eosinophilic phenotype; IL-5 inhibitor